Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore - Wikidata - wikimedia - TriplyDB

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

http://www.wikidata.org/entity/Q58033538

about

Antibiotic treatment of animals infected with Borrelia burgdorferi In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer Alternative strategies for proof-of-principle studies of antibacterial agents Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research Antiviral activity of Bifidobacterium adolescentis SPM1605 against Coxsackievirus B3 A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum Mathematical model of plasmid-mediated resistance to ceftiofur in commensal enteric Escherichia coli of cattle Pharmacokinetics of Ceftiofur Crystalline-Free Acid in Clinically Healthy Dogs (Canis lupus familiaris)Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy Hollow-Fiber Methodology for Pharmacokinetic/Pharmacodynamic Studies of Antimalarial Compounds Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.Continuous clindamycin infusion, an innovative approach to treating bone and joint infections Antimicrobial stewardship in daily practice: Managing an important resource.Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens.Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital.Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery.Correcting a Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility Testing Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.Pharmacokinetics of clindamycin in pregnant women in the peripartum period.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.Ciprofloxacin dosage and emergence of resistance in human commensal bacteria Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation Beyond Susceptible and Resistant, Part I: Treatment of Infections Due to Gram-Negative Organisms With Inducible β-Lactamases Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens Staphylococcus aureus in continuous culture: a tool for the rational design of antibiotic treatment protocols

P2860

Q24650857-E68FCA30-F9E7-452A-98C8-7E8F8FBDD2FE Q24654780-26BA725C-C639-4D7E-97ED-F837A03866DD Q26753831-0332A6AD-BBF2-485D-848C-6EB58468A49C Q26825326-022A8EAE-5A0C-40D2-823B-03C2CDAE448D Q26850895-0BD50D5B-BBCF-477A-937A-339F70C2E80F Q27024682-AE7D57DF-BB08-4D49-8C74-15434C5BE83A Q27026206-6338B404-5130-47A1-BED9-D2D71401E1DA Q28476705-3B0C675A-7B8A-4332-90DC-19CE3656D927 Q28478890-1BA864BE-DE7A-4DEF-B85B-4BFFB3DB9EB8 Q28483752-5490EBFE-3603-4246-9073-FC3D0D640803 Q28603087-8F1808B2-0B0B-4368-88B5-3A5AAE46E622 Q30383012-E4290FAE-ACCE-45EB-A02B-07EFA2ADA4DD Q30395441-E86CC911-5A48-4D63-BD73-13B733656A88 Q30411703-98ECF760-E4E7-4B3B-BF98-AF046270175F Q30519448-01624CC7-B604-40E9-9AD0-4CA1A9B96583 Q30734075-9D14F869-9601-44E7-88A3-7286723E2CB8 Q31029779-741A9203-6F2D-47B5-B989-5DF81D111127 Q31143801-D4377426-0A33-44B2-91D7-8ACE77B1BCB2 Q33508985-1CDEFC11-D5F5-4FB4-AE8E-4AD382CA105E Q33559008-480E4BE0-85D6-49AB-A5B8-E9F30ADE3F13 Q33642866-22DACCFA-9EBB-434B-A007-F9A3EA2DCE76 Q33676144-FB72963E-01B3-4A11-B5B5-62280277C751 Q33676387-A1B5F0A1-D2DA-444B-81F2-83AF3E6AAC80 Q33720333-4A01E908-D605-4D3C-9B38-88126710F6C4 Q33742525-E1456D2A-5FCD-4B83-A1EC-A80770A57664 Q33797920-F29BFB3E-F7D3-445E-8994-F8AEEAEB837A Q33817871-D90AC23E-A8A9-415B-AF68-8E3431C98445 Q33826267-E614F237-DFAD-4688-88A5-86EDFCC6A712 Q33826411-9C95619A-C8BC-4739-AED7-07ADDA76AD8E Q33876423-3AA135CA-D3F4-4DAC-91E2-DAF9587964A7 Q34045319-8938F99C-0081-4191-8122-A7A4E3FA7E18 Q34104262-F6D63BAE-7059-4705-9C1D-1D4D91217220 Q34188814-0083C70D-19D8-47F9-B2B3-6D179EF44FF3 Q34266074-D6663F8B-3563-4EF5-86DD-08B2455705D7 Q34274190-D7042B21-D876-4857-ACB1-7EEC56A35632 Q34297656-9287A7B3-3C65-4D53-A3E7-C88CD26DFC51 Q34298988-3FD00CA3-8700-4BDF-A5D9-E00C4C06BBB0 Q34309574-F2B1972F-EF44-40D7-9F0F-C3A5AC0D88EB Q34381321-E8994B42-736E-4FEE-BAB4-55E1A523D8E0 Q34387384-4D0C05B9-54BF-4FD4-8AC6-A70AF0592863

P2860

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

http://www.wikidata.org/entity/Q58033538

description

im Januar 2007 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2007

@uk

name

Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore

@en

Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore

@nl

type

label

Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore

@en

Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore

@nl

prefLabel

Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore

@en

Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore

@nl

P1433

Q58033538-830A264A-4EF6-45F7-BF15-561F3BF1E3B2

P1476

Q58033538-7FF03531-9A0F-42B4-8D70-E0DFD704E4BF

P2093

Q58033538-1A53CD04-B304-46D5-AA8C-4D21F286C993

Q58033538-67DD5A43-18B7-40F7-86E0-24ED6A240679

Q58033538-713FAB04-0E22-4E35-9217-E0F8FBD92E08

Q58033538-9EC57786-E1F3-457B-857C-C6948A886B2D

Q58033538-C6CAF9F1-81CE-44C8-AAB0-58FC4C6833CC

Q58033538-F5B9D169-EBC3-4524-A2F3-D88C9AC95E57

P304

Q58033538-29E10EBF-8377-452B-93F6-43944856F998

P31

Q58033538-401EC9A5-A636-4433-A1CB-E926F1DD35C6

P356

Q58033538-1A6CB405-F013-4AAD-A428-956154E8AB60

P407

Q58033538-A1A97C8A-A67E-4D33-AB5F-A84113D07F9F

P433

Q58033538-313C1341-0486-42FE-B0C2-705598DBDFC8

P478

Q58033538-9EBCD378-E9E9-442B-BC93-533AD5B3981A

P50

Q58033538-2F5D0AE9-E9DF-4804-B844-31A70432AAEF

P577

Q58033538-C11EB693-4236-43D9-AC6C-911831762741

P698

Q58033538-C3757427-96F7-49DD-84F9-B1341F7F0300

P921

Q58033538-F492D030-FE20-4DA5-AE4B-091A28BE0F65

P356

P1433

Clinical Infectious Diseases

P1476

Antimicrobial Resistance: Phar ...... It’s Not Just for Mice Anymore

@en

P2093

Alan Forrest

http://www.w3.org/2001/XMLSchema#string

Arnold Louie

http://www.w3.org/2001/XMLSchema#string

Christopher M. Rubino

http://www.w3.org/2001/XMLSchema#string

George L. Drusano

http://www.w3.org/2001/XMLSchema#string

Paul G. Ambrose

http://www.w3.org/2001/XMLSchema#string

Sujata M. Bhavnani

http://www.w3.org/2001/XMLSchema#string

P304

79-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/510079

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17143821

http://www.w3.org/2001/XMLSchema#string

P921

antimicrobial resistance